Biotech Values

[tinkershaw]

Were investors placing no value on the Symlin program in obesity?

I was not. The drug is interesting but if I recall correctly AMLN sold their interest for milestones and 20% royalty and it would be at least 5 years to market. Too far away with too much speculation with too little in terms of royalty income to mean much with AMLN's current marketcap.

EXEL is the XL-184 company and AMLN is the bydureon company for better or worse until they come up with something a little closer with more clarity to commercialization.

This said, yeah, it was surprising to see such a non-response as many AMLN bulls focus on this drug.

One point of clarification, unless I missed something (as I might have when I read the headline I figured it was pramlintide and metreleptin and not Symlin) but I don't believe Symlin is the drug in question, it is the combination trial of pralintide and metreleptin that was halted. These are the drugs in the Takeda deal.

Tinker